Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 凯莱英 |
|---|---|
| Other Market Stock Code | 002821 |
| H-Share Offer Price | HK$ 388.00 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Asymchem |
|---|---|
| Stock Code | 06821 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是領先的技術驅動型CDMO公司,提供貫穿藥物開發及生產全過程的綜合解決方案。就小分子藥物提供貫穿臨床前、臨床及商業化階段的工藝開發及生產服務,並將CDMO能力擴展至多肽、寡核苷酸、單克隆抗體(mAb)、抗體偶聯藥物(ADC)及信使RNA (mRNA),以及其他服務,包括藥物製劑解決方案、生物合成解決方案和臨床CRO解決方案。 |
| Listing Date | 2021-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國天津市經濟技術開發區洞庭三街6號 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.asymchem.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 388.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 38,800 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-11-30 to 2021-12-03 |
| Global Offering Shares | 18,415,400 shares |
| HK Public Offer Shares (Initial) | 1,841,600 shares (10.0%) |
| Public Offer Lots (Initial) | 18,416lots (Pool A9,208lots,Pool B9,208lots) |
| International Placing Shares (Initial) | 16,573,800 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 263,076,518 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 7,145,175,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 38,800 |
| 2 lots | 200 | HK$ 77,600 |
| 3 lots | 300 | HK$ 116,400 |
| 4 lots | 400 | HK$ 155,200 |
| 5 lots | 500 | HK$ 194,000 |
| 6 lots | 600 | HK$ 232,800 |
| 7 lots | 700 | HK$ 271,600 |
| 8 lots | 800 | HK$ 310,400 |
| 9 lots | 900 | HK$ 349,200 |
| 10 lots | 1,000 | HK$ 388,000 |
| 15 lots | 1,500 | HK$ 582,000 |
| 20 lots | 2,000 | HK$ 776,000 |
| 25 lots | 2,500 | HK$ 970,000 |
| 30 lots | 3,000 | HK$ 1,164,000 |
| 35 lots | 3,500 | HK$ 1,358,000 |
| 40 lots | 4,000 | HK$ 1,552,000 |
| 45 lots | 4,500 | HK$ 1,746,000 |
| 50 lots | 5,000 | HK$ 1,940,000 |
| 60 lots | 6,000 | HK$ 2,328,000 |
| 70 lots | 7,000 | HK$ 2,716,000 |
| 80 lots | 8,000 | HK$ 3,104,000 |
| 90 lots | 9,000 | HK$ 3,492,000 |
| 100 lots | 10,000 | HK$ 3,880,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 150 lots | 15,000 | HK$ 5,820,000 |
| 200 lots | 20,000 | HK$ 7,760,000 |
| 250 lots | 25,000 | HK$ 9,700,000 |
| 300 lots | 30,000 | HK$ 11,640,000 |
| 400 lots | 40,000 | HK$ 15,520,000 |
| 450 lots | 45,000 | HK$ 17,460,000 |
| 500 lots | 50,000 | HK$ 19,400,000 |
| 600 lots | 60,000 | HK$ 23,280,000 |
| 6,000 lots | 600,000 | HK$ 232,800,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 3.03B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 102,073,688,984 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 7,145,175,200 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币719.7百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 1,822,787 | 2,445,849 | 3,136,724 |
| Cost of sales | -984,677 | -1,345,286 | -1,683,500 |
| Gross profit | 838,110 | 1,100,563 | 1,453,224 |
| Other income and gains, net | 79,306 | 100,482 | 119,773 |
| Selling and distribution expenses | -71,367 | -82,827 | -84,253 |
| Administrative expenses | -214,901 | -275,599 | -320,599 |
| Net finance costs | -1,467 | -1,768 | -3,728 |
| Share of associates and JVs | 0 | 1,469 | 2,084 |
| Profit before tax | 460,498 | 620,554 | 811,233 |
| Income tax expense | -54,141 | -68,965 | -91,530 |
| Profit for the year | 406,357 | 551,589 | 719,703 |
| Profit attributable to owners | 428,202 | 551,589 | 719,742 |
Balance Sheet
| Item | 2018 | 2019 | 2020 | 2021-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 629,971 | 435,252 | 2,124,615 | |
| Trade and bills receivables | 521,396 | 656,908 | 978,149 | |
| Inventories | 424,117 | 448,783 | 726,384 | |
| Total current assets | 1,694,229 | 1,638,628 | 4,030,548 | |
| Total assets | 3,188,076 | 3,788,053 | 7,182,650 | |
| Total current liabilities | 540,604 | 507,437 | 928,583 | |
| Total liabilities | 677,688 | 745,004 | 1,192,900 | |
| Total equity | 2,510,388 | 3,043,049 | 5,989,750 | |
| Equity attributable to owners | 2,510,388 | 3,043,049 | 5,989,789 | |
| Interest-bearing borrowings | 0 | 0 | 10,034 | 0 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 | 2021-06 |
|---|---|---|---|---|
| Net cash from operating activities | 415,899 | 602,034 | 572,913 | |
| Net cash from investing activities | -583,702 | -729,898 | -1,101,772 | |
| Depreciation of PP&E | 100,948 | 120,697 | 153,977 | 93,351 |
| Depreciation of right-of-use assets | 2,496 | 5,212 | 7,772 | 6,311 |
| Amortisation of intangible assets | 1,256 | 2,189 | 3,585 | 1,955 |
| Purchase of PP&E | -543,158 | -510,752 | -1,014,960 | -575,569 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 370.0 |
|---|---|
| First Day Open | HK$ 388.0 |
| First Day Change | -4.64% |
| First Day Volume | 2786450.0 |
| First Day Turnover | 1047110000.0 |
| Use of Proceeds | 1、約20%(或1,370.0百萬港元)將用于進一步提高我們的小分子CDMO解決方案的產能及能力;
2、約35%(或2,397.4百萬港元)將用于加強我們新興服務并擴大我們的服務內容;
3、約20%(或或1,370.0百萬港元)將用于投資研發項目及保持我們的技術領先地位;
4、約15%(或1,027.5百萬港元)將用于選擇性地進行戰略投資及收購;
5、約10%(或685.0百萬港元)將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Hao Hong | — |
| Company Secretary | 徐向科、鄭程傑 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Hao Hong博士通過ALAB持有88,510,520股A股(36.18%),並直接持有10,191,928股A股(4.17%);ALAB直接持有88,510,520股A股(36.18%) |
|---|




